AR061905A1 - 3-AZABICICLO VANILOID RECEIVERS LEGANDS [3.1.0] HEXANE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESSES FOR THEIR PREPARATION - Google Patents
3-AZABICICLO VANILOID RECEIVERS LEGANDS [3.1.0] HEXANE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESSES FOR THEIR PREPARATIONInfo
- Publication number
- AR061905A1 AR061905A1 ARP070103179A ARP070103179A AR061905A1 AR 061905 A1 AR061905 A1 AR 061905A1 AR P070103179 A ARP070103179 A AR P070103179A AR P070103179 A ARP070103179 A AR P070103179A AR 061905 A1 AR061905 A1 AR 061905A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- unsubstituted
- alkyl
- cycloalkenyl
- occurrence
- Prior art date
Links
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 title 3
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 7
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 7
- 229910052739 hydrogen Inorganic materials 0.000 abstract 7
- 239000001257 hydrogen Substances 0.000 abstract 7
- 150000002431 hydrogen Chemical class 0.000 abstract 6
- 125000001072 heteroaryl group Chemical group 0.000 abstract 5
- 125000000623 heterocyclic group Chemical group 0.000 abstract 5
- 125000003342 alkenyl group Chemical group 0.000 abstract 4
- 125000000304 alkynyl group Chemical group 0.000 abstract 4
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 4
- 229910052757 nitrogen Inorganic materials 0.000 abstract 4
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 4
- 125000004043 oxo group Chemical group O=* 0.000 abstract 4
- 125000004149 thio group Chemical group *S* 0.000 abstract 4
- 229910003827 NRaRb Inorganic materials 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 3
- 102000011040 TRPV Cation Channels Human genes 0.000 abstract 2
- 108010062740 TRPV Cation Channels Proteins 0.000 abstract 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- -1 cyano, formyl Chemical group 0.000 abstract 2
- 125000004122 cyclic group Chemical group 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 125000004415 heterocyclylalkyl group Chemical group 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 201000004384 Alopecia Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000015943 Coeliac disease Diseases 0.000 abstract 1
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000003251 Pruritus Diseases 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 231100000360 alopecia Toxicity 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 201000001119 neuropathy Diseases 0.000 abstract 1
- 230000007823 neuropathy Effects 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 125000006239 protecting group Chemical group 0.000 abstract 1
- 206010039083 rhinitis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
utiles como ligandos de receptores vaniloides, métodos para el tratamiento de enfermedades, condiciones y/o trastornos modulados por receptores vaniloides como dolor, migrana, neuropatías, trastornos gastrointestinales, Crohn, celiaquía, rinitis, alergia, asma, prurito, depresion, artritis, alopecia, ansiedad. Reivindicacion 1: Un Compuesto de la formula general (1) o una prodroga del mismo, una sal farmacéuticamente aceptable del mismo, un N-oxido del mismo, un éster del mismo, un solvato del mismo, un tautomero del mismo, un estereoisomero del mismo o un polimorfo del mismo, en donde: X es O o S; R1 se selecciona de las estructuras del grupo de formulas (2), en donde R1 está unida a la estructura principal a través de cualquier átomo de carbono en el anillo y se substituye opcionalmente con uno o más grupos R; cada ocurrencia de R y R6 se selecciona independientemente de hidrogeno, nitro, ciano, formilo, acetilo, halogeno, -OR7, -SR7, oxo, tio, alquilo substituido o no substituido, alquenilo substituido o no substituido, alquinilo substituido o no substituido, cicloalquilo substituido o no substituido, cicloalquilalquilo substituido o no substituido, cicloalquenilo substituido o no substituido, cicloalquenilalquilo substituido o no substituido, arilo substituido o no substituido, arilalquilo substituido o no substituido, heteroarilo substituido o no substituido, heteroarilalquilo substituido o no substituido, grupo heterocíclico substituido o no substituido, heterociclilalquilo substituido o no substituido, -C(O)R7, -C(O)O-R7, -C(O)NR7R8 , -NR7R8, -S(O)m-R7, S(O)m-NR7R8, y un grupo de proteccion; cada ocurrencia de R7 y R8 se selecciona independientemente de hidrogeno, nitro, halo, ciano, -ORa, -SRa, oxo, tio, alquilo substituido o no substituido, alquenilo substituido o no substituido, alquinilo substituido o no substituido, cicloalquilo substituido o no substituido, cicloalquilalquilo substituido o no substituido, cicloalquenilo substituido o no substituido, cicloalquenilalquilo substituido o no substituido, arilo substituido o no substituido, arilalquilo substituido o no substituido, heteroarilo substituido o no substituido, heteroarilalquilo substituido o no substituido, un grupo heterocíclico substituido o no substituido, heterociclilalquilo substituido o no substituido, -C(O)Ra, -C(O)O-Ra, -C(O)NRaRb, -S(O)m-Ra, -S(O)m-NRaRb, -NRaRb, y un grupo de proteccion, o R7 y R8, cuando ambos están directamente unidos al mismo átomo de nitrogeno, se juntan con el átomo de nitrogeno al cual están unidos para formar un anillo cíclico no saturado o saturado de 3 a 7 miembros opcionalmente substituido, el cual incluye opcionalmente uno o más heteroátomos seleccionados de O, NRa y S; cada ocurrencia de Ra y Rb se selecciona independientemente de hidrogeno, halogeno, nitro, ciano, formilo, acetilo, oxo, tio, -C(O)-Rc, -C(O)ORc, -C(O)NRcRd, -S(O)m-Rc, S(O)m-NRcRd, -NRcRd, -ORc, -SRd, un grupo de proteccion, alquilo substituido o no substituido, alquenilo substituido o no substituido, alquinilo substituido o no substituido, cicloalquilo substituido o no substituido, cicloalquilalquilo substituido o no substituido, cicloalquenilo substituido o no substituido, cicloalquenilalquilo substituido o no substituido, arilo substituido o no substituido, arilalquilo substituido o no substituido, heteroarilo substituido o no substituido, un grupo heterocíclico substituido o no substituido, heterocicliloalquilo substituido o no substituido, y un heteroarilalquilo substituido o no substituido; cada ocurrencia de Rc y Rd se selecciona independientemente de hidrogeno, alquilo substituido o no substituido, alquenilo substituido o no substituido, alquinilo substituido o no substituido, cicloalquilo substituido o no substituido, cicloalquilalquilo substituido o no substituido, cicloalquenilo substituido o no substituido, cicloalquenilalquilo substituido o no substituido, arilo substituido o no substituido, ariloalquilo substituido o no substituido, heteroarilo substituido o no substituido, un grupo heterocíclico substituido o no substituido, heterociclilalquilo substituido o no substituido, o un heteroarilalquilo substituido o no substituido y un grupo de proteccion, o Rc y Rd, cuando ambos se encuentran directamente unidos al mismo átomo de nitrogeno, se unen con el átomo de nitrogeno al cual están unidos para formar un anillo cíclico saturado o no saturado de 3 a 7 miembros substituido opcionalmente, el cual incluye uno o más heteroátomos seleccionados de O, NRe o S; cada ocurrencia de Re se selecciona independientemente de hidrogeno o de alquilo substituido o no substituido, cada ocurrencia de m es 0, 1 o 2; R2 y R3 se seleccionan independientemente de hidrogeno, hidroxi y alquilo C1-6; y cada ocurrencia de R4 y R5 se selecciona independientemente de hidrogeno, halogeno, y alquilo, o cuando R4 y R5 están unidos al mismo átomo de carbono R4 y R5 forman conjuntamente un grupo oxo o un grupo tio.Useful as vanilloid receptor ligands, methods for the treatment of diseases, conditions and / or disorders modulated by vanilloid receptors such as pain, migraine, neuropathies, gastrointestinal disorders, Crohn, celiac disease, rhinitis, allergy, asthma, pruritus, depression, arthritis, alopecia anxiety Claim 1: A Compound of the general formula (1) or a prodrug thereof, a pharmaceutically acceptable salt thereof, an N-oxide thereof, an ester thereof, a solvate thereof, a tautomer thereof, a stereoisomer of the same or a polymorph thereof, where: X is O or S; R1 is selected from the structures of the group of formulas (2), wherein R1 is attached to the main structure through any carbon atom in the ring and is optionally substituted with one or more R groups; Each occurrence of R and R6 is independently selected from hydrogen, nitro, cyano, formyl, acetyl, halogen, -OR7, -SR7, oxo, thio, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroaryl, heterocyclic group substituted or unsubstituted, heterocyclyl substituted or unsubstituted alkyl, -C (O) R7, -C (O) O-R7, -C (O) NR7R8, -NR7R8, -S (O) m-R7, S (O) m-NR7R8, and a protection group; each occurrence of R7 and R8 is independently selected from hydrogen, nitro, halo, cyano, -ORa, -SRa, oxo, thio, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl substituted, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, a substituted or unsubstituted heteroaryl alkyl substituted, substituted or unsubstituted heterocyclylalkyl, -C (O) Ra, -C (O) O-Ra, -C (O) NRaRb, -S (O) m-Ra, -S (O) m-NRaRb, - NRaRb, and a protection group, or R7 and R8, when both are directly attached to the same nitrogen atom, join the nitrogen atom to which they are attached to form an unsaturated or saturated cyclic ring of 3 to 7 opc members ionically substituted, which optionally includes one or more heteroatoms selected from O, NRa and S; Each occurrence of Ra and Rb is independently selected from hydrogen, halogen, nitro, cyano, formyl, acetyl, oxo, thio, -C (O) -Rc, -C (O) ORc, -C (O) NRcRd, -S (O) m-Rc, S (O) m-NRcRd, -NRcRd, -ORc, -SRd, a protection group, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted cycloalkyl or unsubstituted, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, a substituted or unsubstituted heterocyclic group, heterocyclyl or substituted alkyl unsubstituted, and a substituted or unsubstituted heteroarylalkyl; each occurrence of Rc and Rd is independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted cycloalkenyl, substituted cycloalkenyl alkyl or unsubstituted, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, a substituted or unsubstituted heterocyclic group, substituted or unsubstituted heterocyclyl alkyl, or a substituted or unsubstituted heteroarylalkyl and a protecting group, or Rc and Rd, when both are directly attached to the same nitrogen atom, bind with the nitrogen atom to which they are attached to form a 3 to 7-membered saturated or unsaturated cyclic ring optionally substituted, which includes one or more heteroatoms selected from O, NRe or S; each occurrence of Re is independently selected from hydrogen or substituted or unsubstituted alkyl, each occurrence of m is 0, 1 or 2; R2 and R3 are independently selected from hydrogen, hydroxy and C1-6 alkyl; and each occurrence of R4 and R5 is independently selected from hydrogen, halogen, and alkyl, or when R4 and R5 are attached to the same carbon atom R4 and R5 together form an oxo group or a thio group.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1136MU2006 | 2006-07-17 | ||
| US83556006P | 2006-08-03 | 2006-08-03 | |
| IN381MU2007 | 2007-02-27 | ||
| US89367507P | 2007-03-08 | 2007-03-08 | |
| US94771507P | 2007-07-03 | 2007-07-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR061905A1 true AR061905A1 (en) | 2008-10-01 |
Family
ID=38928004
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070103179A AR061905A1 (en) | 2006-07-17 | 2007-07-17 | 3-AZABICICLO VANILOID RECEIVERS LEGANDS [3.1.0] HEXANE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESSES FOR THEIR PREPARATION |
Country Status (2)
| Country | Link |
|---|---|
| AR (1) | AR061905A1 (en) |
| WO (1) | WO2008010061A2 (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CL2008002053A1 (en) | 2007-07-17 | 2009-05-22 | Hoffmann La Roche | Method for the purification of a monopeglated erythropoietin (epompeg) which consists of providing a solution containing mono, poly and non-peglated erythropoietin and passing it through two steps of cation exchange chromatography and a method to produce epo mpeg that includes a purification method. |
| AR067536A1 (en) | 2007-07-17 | 2009-10-14 | Hoffmann La Roche | METHOD FOR OBTAINING A MONO-PEGILATED ERYTHROPOYETIN IN A SUBSTANTIALLY HOMOGENOUS FORM |
| EP2025674A1 (en) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs |
| WO2009034433A2 (en) * | 2007-09-10 | 2009-03-19 | Glenmark Pharmaceuticals, S.A. | 3-azabicyclo [3.1.0] hexane derivatives as vanilloid receptor ligands |
| WO2009090548A2 (en) * | 2008-01-17 | 2009-07-23 | Glenmark Pharmaceuticals, S.A. | 3-azabicyclo [3.1.0] hexane derivatives as vanilloid receptor ligands |
| MX2013002011A (en) * | 2010-08-20 | 2013-03-25 | Gruenenthal Gmbh | Substituted cyclic carboxamide and urea derivatives as ligands of the vanilloid receptor. |
| MX2016016202A (en) * | 2014-06-12 | 2017-07-28 | Allocyte Pharmaceuticals Ag | Small molecule lfa-1 inhibitors. |
| WO2020243415A2 (en) | 2019-05-31 | 2020-12-03 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
| MX2021014441A (en) * | 2019-05-31 | 2022-01-06 | Ikena Oncology Inc | Tead inhibitors and uses thereof. |
| CN114793434A (en) | 2019-10-18 | 2022-07-26 | 加利福尼亚大学董事会 | 3-Phenylsulfonyl-quinoline derivatives as agents for the treatment of pathogenic vascular disorders |
| RU2755206C1 (en) | 2020-05-20 | 2021-09-14 | Федеральное государственное бюджетное учреждение науки Тихоокеанский институт биоорганической химии им. Г.Б. Елякова Дальневосточного отделения Российской академии наук (ТИБОХ ДВО РАН) | Agent with prolonged analgesic action and medicinal product based thereon |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5256791A (en) * | 1992-03-02 | 1993-10-26 | Pfizer Inc. | Preparation of intermediates in the synthesis of quinoline antibiotics |
| US5475116A (en) * | 1994-04-29 | 1995-12-12 | Pfizer Inc. | Aza bicyclo[3,1,0]hexane intermediates useful in the synthesis of quinolones |
| US6184380B1 (en) * | 1999-01-25 | 2001-02-06 | Pfizer Inc. | Process for preparing naphthyridones and intermediates |
| EP1006113A1 (en) * | 1998-12-02 | 2000-06-07 | Pfizer Products Inc. | Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use to inhibit abnormal cell growth |
| GB0110901D0 (en) * | 2001-05-02 | 2001-06-27 | Smithkline Beecham Plc | Novel Compounds |
| US7232835B2 (en) * | 2002-12-10 | 2007-06-19 | Ranbaxy Laboratories Limited | 3,6-Disubstituted azabicyclo derivatives as muscarinic receptor antagonists |
| ATE440835T1 (en) * | 2003-03-06 | 2009-09-15 | Glaxo Group Ltd | HETEROCYCLIC UREA DERIVATIVES FOR THE TREATMENT OF PAIN. |
| GB0325287D0 (en) * | 2003-10-29 | 2003-12-03 | Merck Sharp & Dohme | Therapeutic agents |
| WO2007029086A2 (en) * | 2005-09-05 | 2007-03-15 | Ranbaxy Laboratories Limited | Derivatives of 3-azabicyclo[3.1.0]hexane as dipeptidyl peptidase-iv inhibitors |
| US20090156465A1 (en) * | 2005-12-30 | 2009-06-18 | Sattigeri Jitendra A | Derivatives of beta-amino acid as dipeptidyl peptidase-iv inhibitors |
-
2007
- 2007-07-16 WO PCT/IB2007/002002 patent/WO2008010061A2/en not_active Ceased
- 2007-07-17 AR ARP070103179A patent/AR061905A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008010061A2 (en) | 2008-01-24 |
| WO2008010061A3 (en) | 2008-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR061905A1 (en) | 3-AZABICICLO VANILOID RECEIVERS LEGANDS [3.1.0] HEXANE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESSES FOR THEIR PREPARATION | |
| AR084849A1 (en) | DERIVATIVES OF OXAZINE AND ITS USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | |
| AR076765A1 (en) | ANTIVIRAL COMPOUNDS | |
| AR065622A1 (en) | DERIVATIVES OF 3-CIANO -4- (4-PHENYL- PIPERIDIN -1- IL) PIRIDIN -2- ONA | |
| PE20161372A1 (en) | ROR-GAMMA DIHYDROPYRROLOPYRIDINE INHIBITORS | |
| EA200901160A1 (en) | DERIVATIVES 3-CYANO-4- (4-TETRAGIDROPIRANPHENYL) PYRIDIN-2-IT | |
| AR077267A1 (en) | SELECTED INHIBITING NITROGEN DERIVATIVES OF PI3K, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME IN THE TREATMENT OF INFLAMMATORY AND / OR AUTOIMMUNE DISEASES. | |
| NI201500106A (en) | DERIVATIVES OF BENZOTHIOPHENE AND COMPOSITIONS OF THE SAME AS SELECTIVE DEGRADANTS OF THE RECEPTORS OF ESTRÓGEN. | |
| AR076936A1 (en) | CARBAMATE AND UREA INHIBITORS OF THE 11 BETA HYDROXIESTEROID DEHYDROGENASE 1 | |
| AR049300A1 (en) | MGLUR1 ANTAGONIST TRICICLIC COMPOUNDS AS THERAPEUTIC AGENTS | |
| EA200901162A1 (en) | 1,4-Disposable 3-cyanopyridone derivatives and their use as positive modulators of the MGLUR2 receptor | |
| AR085960A1 (en) | 1,3-OXAZINES AS INHIBITORS OF THE BACE1 AND / OR THE BACE2 | |
| AR081045A1 (en) | DERIVATIVES OF QUINAZOLINEDIONA AS TRPA1 MODULATORS | |
| AR080878A1 (en) | HETEROCICLIC DERIVATIVES OF ARYLETINYL, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM, METHOD FOR PREPARING THEM AND USE OF THE SAME IN THE TREATMENT OF CHICHOPHRENIA AND COGNITIVE DISORDERS. | |
| EA201791271A1 (en) | THIAZOLES, SUBSTITUTED BY CARBOXAMIDE OR SULPHONAMIDE AND RELATED DERIVATIVES AS MODULATORS FOR ORPHANIC NUCLEAR RORγ RECEPTOR | |
| AR100715A1 (en) | DERIVATIVES OF RENT OF COMPOUNDS 1-OXA-4,9-DIAZAESPIRO UNDECENE THAT HAVE MULTIMODAL ACTIVITY AGAINST PAIN | |
| EA201370184A1 (en) | Heteroaryl Derivatives | |
| AR063147A1 (en) | INHIBITING NITROGEN HETEROCICLIC COMPOUNDS OF HISTAMINE H3 RECEPTORS, PREPARATION METHOD, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS. | |
| JP2019532067A5 (en) | ||
| MA34094B1 (en) | 3- (HETEROARYLAMINO) -1,2,3,4-TETRAHYDRO-9H-CARBAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF THE PROSTAGLANDIN D2 RECEPTOR | |
| AR100714A1 (en) | 1-OXA-4,9-DIAZAESPIRO UNDECANO COMPOUND RENTAL AND ARYL DERIVATIVES THAT HAVE MULTIMODAL ACTIVITY AGAINST PAIN | |
| ECSP10010606A (en) | QUINUCLIDINE DERIVATIVES AS M3 MUSCARINIC RECEPTORS ANTAGONISTS | |
| MY197742A (en) | Morphinan derivative | |
| AR111176A1 (en) | PIRAZOL DERIVATIVES [1,5-A] PIRIMIDINE SUBSTITUTED WITH PHARMACOLOGICALLY ACTIVE ALICYCLES | |
| PE20171089A1 (en) | NEW BENZIMIDAZOLE DERIVATIVES AS ANTIHISTAMINE AGENTS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |